{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:51:58Z","timestamp":1761630718606},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,3,21]],"date-time":"2015-03-21T00:00:00Z","timestamp":1426896000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s10198-015-0679-8","type":"journal-article","created":{"date-parts":[[2015,3,20]],"date-time":"2015-03-20T13:36:24Z","timestamp":1426858584000},"page":"287-304","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A cost-utility analysis of ingenol mebutate gel for the treatment of actinic keratosis: a Scottish perspective"],"prefix":"10.1007","volume":"17","author":[{"given":"Keith","family":"Tolley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danny","family":"Kemmett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Signe","family":"Thybo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Nasr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Smethurst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,3,21]]},"reference":[{"issue":"6","key":"679_CR1","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1365-2133.1986.tb06644.x","volume":"115","author":"R Marks","year":"1986","unstructured":"Marks, R., Foley, P., Goodman, G., Hage, B.H., Selwood, T.S.: Spontaneous remission of solar keratoses: the case for conservative management. Br. J. Dermatol. 115(6), 649\u2013655 (1986)","journal-title":"Br. J. Dermatol."},{"key":"679_CR2","unstructured":"Primary Care Dermatology Society: Actinic keratosis (syn. solar keratosis). http:\/\/www.pcds.org.uk\/image-atlas\/a-z-of-diagnosis\/50-image-atlas-detailed-articles\/73-actinic-keratosis (2010)"},{"issue":"8","key":"679_CR3","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/bjc.1996.534","volume":"74","author":"I Harvey","year":"1996","unstructured":"Harvey, I., Frankel, S., Marks, R., Shalom, D., Nolan-Farrell, M.: Non-melanoma skin cancer and solar keratoses. I. Methods and descriptive results of the South Wales Skin Cancer Study. Br. J. Cancer 74(8), 1302\u20131307 (1996)","journal-title":"Br. J. Cancer"},{"issue":"5","key":"679_CR4","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2340\/00015555-0523","volume":"88","author":"G Tinghog","year":"2008","unstructured":"Tinghog, G., Carlsson, P., Synnerstad, I., Rosdahl, I.: Societal cost of skin cancer in Sweden in 2005. Acta Derm. Venereol. 88(5), 467\u2013473 (2008). doi: 10.2340\/00015555-0523","journal-title":"Acta Derm. Venereol."},{"issue":"3","key":"679_CR5","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s10198-008-0127-0","volume":"10","author":"S Morris","year":"2009","unstructured":"Morris, S., Cox, B., Bosanquet, N.: Cost of skin cancer in England. European J. Health Econ. 10(3), 267\u2013273 (2009). doi: 10.1007\/s10198-008-0127-0","journal-title":"European J. Health Econ."},{"key":"679_CR6","unstructured":"Cancer Research UK: Skin cancer mortality statistics. http:\/\/www.cancerresearchuk.org\/cancer-info\/cancerstats\/types\/skin\/mortality\/#source14 (2013). Accessed July 2013"},{"issue":"11","key":"679_CR7","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1002\/cncr.24284","volume":"115","author":"VD Criscione","year":"2009","unstructured":"Criscione, V.D., Weinstock, M.A., Naylor, M.F., Luque, C., Eide, M.J., Bingham, S.F.: Actinic keratoses: natural history and risk of malignant transformation in the Veterans affairs topical tretinoin chemoprevention trial. Cancer 115(11), 2523\u20132530 (2009). doi: 10.1002\/cncr.24284","journal-title":"Cancer"},{"key":"679_CR8","doi-asserted-by":"crossref","unstructured":"Einspahr, J.G., Stratton, S.P., Bowden, G.T., Alberts, D.S.: Chemoprevention of human skin cancer. Crit Rev Oncol Hematol 41(3):269\u2013285 (2002). pii: S1040842801001858","DOI":"10.1016\/S1040-8428(01)00185-8"},{"issue":"4","key":"679_CR9","first-page":"201","volume":"87","author":"SR Feldman","year":"2011","unstructured":"Feldman, S.R., Fleischer Jr, A.B.: Progression of actinic keratosis to squamous cell carcinoma revisited: clinical and treatment implications. Cutis 87(4), 201\u2013207 (2011)","journal-title":"Cutis"},{"key":"679_CR10","unstructured":"Scottish Medicines Consortium: Imiquimod 5% cream (Aldara\u00ae). Meda Pharmaceuticals. SMC No. (385\/07). http:\/\/www.scottishmedicines.org.uk\/SMC_Advice\/Advice\/385_07_imiquimod_cream__Aldara_\/imiquimod_cream__Aldara_ (2008). Accessed July 2013"},{"key":"679_CR11","unstructured":"Scottish Medicines Consortium (SMC): Methyl aminolevulinate 160\u00a0mg\/g cream (Metvix\u00ae). Galderma Ltd. SMC No. (50\/03) Available at: http:\/\/www.scottishmedicines.org.uk\/SMC_Advice\/Advice\/Methyl_amonolevulinate__Metvix_cream__174___for_actinic_keratoses\/Methyl_aminolevulinate__Metvix_cream__ (2003). Accessed July 2013"},{"key":"679_CR12","unstructured":"Scottish Medicines Consortium: 5-aminolaevulinic acid (as hydrochloride), 78\u00a0mg\/g, gel (Ameluz\u00ae). SMC No. (811\/12) (2012)"},{"key":"679_CR13","unstructured":"NHS Scotland, S.D.S.: Solar (Actinic) keratoses and Bowen\u2019s disease. Dermatology referral and management pathway (2010)"},{"key":"679_CR14","unstructured":"eMC: Summary of Product Characteristics: Actikerall 5\u00a0mg\/g\u00a0+\u00a0100\u00a0mg\/g Cutaneous Solution. http:\/\/www.medicines.org.uk\/EMC\/medicine\/24614\/SPC\/Actikerall+5mg+g+%2B+100mg+g+Cutaneous+Solution\/ (2011). Accessed July 2013"},{"key":"679_CR15","unstructured":"eMC: Summary of Product Characteristics: Solaraze. http:\/\/www.medicines.org.uk\/emc\/medicine\/21229 ) (2012). Accessed July 2013"},{"key":"679_CR16","unstructured":"eMC: Summary of Product Characteristics: Efudix Cream. http:\/\/www.medicines.org.uk\/emc\/medicine\/6219\/SPC\/Efudix+Cream\/ (2011). Accessed July 2013"},{"issue":"2","key":"679_CR17","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1001\/archdermatol.2008.562","volume":"145","author":"B Yentzer","year":"2009","unstructured":"Yentzer, B., Hick, J., Williams, L., Inabinet, R., Wilson, R., Camacho, F.T., Russell, G.B., Feldman, S.R.: Adherence to a topical regimen of 5-fluorouracil, 0.5%, cream for the treatment of actinic keratoses. Arch. Dermatol. 145(2), 203\u2013205 (2009)","journal-title":"Arch. Dermatol."},{"issue":"11","key":"679_CR18","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2165\/11538670-000000000-00000","volume":"28","author":"EC Wilson","year":"2010","unstructured":"Wilson, E.C.: Cost effectiveness of imiquimod 5% cream compared with methyl aminolevulinate-based photodynamic therapy in the treatment of non-hyperkeratotic, non-hypertrophic actinic (solar) keratoses: a decision tree model. Pharmacoeconomics 28(11), 1055\u20131064 (2010)","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"679_CR19","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1001\/archderm.1997.03890420065007","volume":"133","author":"EW Jeffes","year":"1997","unstructured":"Jeffes, E.W., McCullough, J.L., Weinstein, G.D., Fergin, P.E., Nelson, J.S., Shull, T.F., Simpson, K.R., Bukaty, L.M., Hoffman, W.L., Fong, N.L.: Photodynamic therapy of actinic keratosis with topical 5-aminolevulinic acid. A pilot dose-ranging study. Arch. Dermatol. 133(6), 727\u2013732 (1997)","journal-title":"Arch. Dermatol."},{"issue":"9","key":"679_CR20","first-page":"1049","volume":"10","author":"AF Taub","year":"2011","unstructured":"Taub, A.F., Garretson, C.B.: A randomized, blinded, bilateral intraindividual, vehicle-controlled trial of the use of photodynamic therapy with 5-aminolevulinic acid and blue light for the treatment of actinic keratoses of the upper extremities. J. Drugs Dermatol. 10(9), 1049\u20131056 (2011)","journal-title":"J. Drugs Dermatol."},{"issue":"3","key":"679_CR21","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1159\/000246376","volume":"192","author":"RM Szeimies","year":"1996","unstructured":"Szeimies, R.M., Karrer, S., Sauerwald, A., Landthaler, M.: Photodynamic therapy with topical application of 5-aminolevulinic acid in the treatment of actinic keratoses: an initial clinical study. Dermatology 192(3), 246\u2013251 (1996)","journal-title":"Dermatology"},{"key":"679_CR22","unstructured":"Ulrich, M., V\u00f6lker-Call, M., Lange-Asschenfeldt, S., R\u00f6wert-Huber, J., \u00d8sterdal, M.L., Skak, K., Skov, T., Stockfleth, E.: Biological effects of ingenol mebutate gel, 0.05%, for the treatment of actinic keratosis as assessed by reflectance confocal microscopy. Poster presented at American Academy of Dermatology Summer Academy Meeting Aug 15\u201319 2012, Boston, MA. USA. (2) (2012)"},{"issue":"11","key":"679_CR23","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1056\/NEJMoa1111170","volume":"366","author":"M Lebwohl","year":"2012","unstructured":"Lebwohl, M., Swanson, N., Anderson, L.L., Melgaard, A., Xu, Z., Berman, B.: Ingenol mebutate gel for actinic keratosis. N. Engl. J. Med. 366(11), 1010\u20131019 (2012)","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"679_CR24","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1080\/09546630902887211","volume":"20","author":"D Muston","year":"2009","unstructured":"Muston, D., Downs, A., Rives, V.: An economic evaluation of topical treatments for actinic keratosis. J Dermatolog Treat 20(5), 266\u2013275 (2009)","journal-title":"J Dermatolog Treat"},{"key":"679_CR25","unstructured":"ISD Scotland: Prescription Cost Analysis for financial year 2011\/12. http:\/\/www.isdscotland.org\/Health-Topics\/Prescribing-and-Medicines\/Publications\/data-tables.asp (2012)"},{"key":"679_CR26","unstructured":"Dias, S., Welton, N.J., Sutton, A.J., Ades, A.E.: NICE DSU technical support document 5: Evidence synthesis in the baseline natural history model. http:\/\/www.nicedsu.org.uk\/TSD5%20Baseline.final%20report.08.05.12.pdf (2011)"},{"issue":"Suppl 2","key":"679_CR27","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2133.2007.08271.x","volume":"157","author":"N Krawtchenko","year":"2007","unstructured":"Krawtchenko, N., Roewert-Huber, J., Ulrich, M., Mann, I., Sterry, W., Stockfleth, E.: A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br. J. Dermatol. 157(Suppl 2), 34\u201340 (2007)","journal-title":"Br. J. Dermatol."},{"key":"679_CR28","unstructured":"eMC: Summary of Product Characteristics: Picato 150 mcg\/g Gel. http:\/\/www.medicines.org.uk\/emc\/medicine\/27246\/SPC\/Picato+150+mcg+g+Gel\/ (2012). Accessed July 2013"},{"issue":"5","key":"679_CR29","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/j.1365-2133.2011.10387.x","volume":"165","author":"E Stockfleth","year":"2011","unstructured":"Stockfleth, E., Kerl, H., Zwingers, T., Willers, C.: Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. Br. J. Dermatol. 165(5), 1101\u20131108 (2011)","journal-title":"Br. J. Dermatol."},{"issue":"6","key":"679_CR30","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1177\/0272989X03259817","volume":"23","author":"B Littenberg","year":"2003","unstructured":"Littenberg, B., Partilo, S., Licata, A., Kattan, M.W.: Paper Standard Gamble: the reliability of a paper questionnaire to assess utility. Med. Decis. Making 23(6), 480\u2013488 (2003). doi: 10.1177\/0272989X03259817","journal-title":"Med. Decis. Making"},{"issue":"2","key":"679_CR31","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1046\/j.1087-0024.2003.09112.x","volume":"9","author":"SC Chen","year":"2004","unstructured":"Chen, S.C., Bayoumi, A.M., Soon, S.L., Aftergut, K., Cruz, P., Sexton, S.A., McCall, C.O., Goldstein, M.K.: A catalog of dermatology utilities: a measure of the burden of skin diseases. J Investig Dermatol Symp Proc 9(2), 160\u2013168 (2004). doi: 10.1046\/j.1087-0024.2003.09112.x","journal-title":"J Investig Dermatol Symp Proc"},{"key":"679_CR32","unstructured":"MIMS: Monthly Index of Medical Specialities (MIMS). Haymarket Medical Media, London (July 2012)"},{"key":"679_CR33","unstructured":"Thomas, K.S., Keogh-Brown, M.R., Chalmers, J.R., Fordham, R.J., Holland, R.C., Armstrong, S.J., Bachmann, M.O., Howe, A.H., Rodgers, S., Avery, A.J., Harvey, I., Williams, H.C.: Effectiveness and cost-effectiveness of salicylic acid and cryotherapy for cutaneous warts. An economic decision model. Health Technol Assess 10(25), iii, ix-87 (2006). doi:02-12-03 [pii]"},{"key":"679_CR34","volume-title":"Unit Costs of Health and Social Care 2011","author":"L Curtis","year":"2011","unstructured":"Curtis, L.: Unit Costs of Health and Social Care 2011. Personal Social Services Research Unit, Canterbury (2011)"},{"key":"679_CR35","unstructured":"ISD Scotland: Acute medical costs R044X: Specialty group costs\u2014consultant outpatients (2011)"},{"issue":"5","key":"679_CR36","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2165\/00019053-200017050-00006","volume":"17","author":"AH Briggs","year":"2000","unstructured":"Briggs, A.H.: Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 17(5), 479\u2013500 (2000)","journal-title":"Pharmacoeconomics"},{"key":"679_CR37","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1146\/annurev.publhealth.23.100901.140534","volume":"23","author":"AH Briggs","year":"2002","unstructured":"Briggs, A.H., O\u2019Brien, B.J., Blackhouse, G.: Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annu. Rev. Public Health 23, 377\u2013401 (2002)","journal-title":"Annu. Rev. Public Health"},{"key":"679_CR38","unstructured":"Scottish Medicines Consortium: ingenol mebutate, 150 & 500micrograms\/g, gel (Picato\u00ae) SMC No. (851\/13). http:\/\/www.scottishmedicines.org.uk\/files\/advice\/ingenol_mebutate_gel_Picato_FINAL_FEBRUARY_2013_amended_04.03.13_for_website.pdf (2013). Accessed Aug 2013"},{"key":"679_CR39","unstructured":"Scottish Medicines Consortium: Guidance to manufacturers for completion of New Product Assessment Form (NPAF). (2012)"},{"issue":"2","key":"679_CR40","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jaad.2007.01.047","volume":"57","author":"J Jorizzo","year":"2007","unstructured":"Jorizzo, J., Dinehart, S., Matheson, R., Moore, J.K., Ling, M., Fox, T.L., McRae, S., Fielder, S., Lee, J.H.: Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3\u00a0days per week in one or two courses of treatment for actinic keratoses on the head. J. Am. Acad. Dermatol. 57(2), 265\u2013268 (2007)","journal-title":"J. Am. Acad. Dermatol."},{"issue":"1","key":"679_CR41","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1046\/j.1440-0960.2002.00635.x","volume":"44","author":"K Gebauer","year":"2003","unstructured":"Gebauer, K., Brown, P., Varigos, G.: Topical diclofenac in hyaluronan gel for the treatment of solar keratoses. Australas. J. Dermatol. 44(1), 40\u201343 (2003)","journal-title":"Australas. J. Dermatol."},{"issue":"2","key":"679_CR42","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jaad.2009.02.022","volume":"61","author":"MA Weinstock","year":"2009","unstructured":"Weinstock, M.A., Lee, K.C., Chren, M.M., Marcolivio, K.: Quality of life in the actinic neoplasia syndrome: the VA Topical Tretinoin Chemoprevention (VATTC) Trial. J. Am. Acad. Dermatol. 61(2), 207\u2013215 (2009)","journal-title":"J. Am. Acad. Dermatol."},{"key":"679_CR43","unstructured":"European Dermatology Forum: Guideline on Actinic Keratoses (update) (2011)"}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-015-0679-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10198-015-0679-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-015-0679-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T01:46:30Z","timestamp":1566438390000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10198-015-0679-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,21]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["679"],"URL":"https:\/\/doi.org\/10.1007\/s10198-015-0679-8","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,21]]}}}